An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms MEASURE 1 ext
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 Dec 2018 4-year results published in the Rheumatology
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 16 Oct 2018 According to a Novartis media release, data from the study, will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.